LSD1/ER-IN-1

LSD1/ER-IN-1

• UNSPSC Description: LSD1/ER-IN-1 (compound 11g) is a potent ER and LSD1 inhibitor, with an IC50 of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC50 of 8.79 μM[1].
• Target Antigen: Apoptosis; Estrogen Receptor/ERR; Histone Demethylase
• Type: Reference compound
• Related Pathways: Apoptosis;Epigenetics;Vitamin D Related/Nuclear Receptor
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/lsd1-er-in-1.html
• Solubility: 10 mM in DMSO
• Smiles: O=S(C1[C@H]2C(C3=CC=C(O)C=C3)=C(C4=CC=C(O)C=C4)[C@@H](C1)O2)(OC5=NC(F)=CC=C5)=O
• Molecular Weight: 455.46
• References & Citations: [1]He M, et al. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer. Eur J Med Chem. 2020 Jun 1;195:112281.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported